Literature DB >> 17049715

Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity.

A P Nácul1, C D Andrade, P Schwarz, P I Homem de Bittencourt, P M Spritzer.   

Abstract

OBJECTIVE: Nitric oxide (NO) and fibrinogen levels, two markers of vascular disease, are associated with insulin resistance, a common trait in women with polycystic ovary syndrome (PCOS). STUDY
DESIGN: Case-control study including 31 women with PCOS and 21 age-matched women with regular, ovulatory cycles, normal androgen levels and idiopathic hirsutism (control group). Nitrite/nitrate concentration (index of endothelium-derived NO) and fibrinogen plasma levels were assessed and analysed in association with anthropometric, metabolic and hormonal variables.
RESULTS: The groups were similar in terms of age, positive family history of diabetes and Ferriman-Gallwey hirsutism score. Nitrite/nitrate and fibrinogen levels were also similar in the two groups. In contrast, in PCOS patients, insulin levels and the homeostatic model assessment were negatively correlated with NO production (r=-0.39, p=0.03 and r=-0.41, p=0.02, respectively). Age, BMI, waist circumference and waist-to-hip ratio were positively correlated with fibrinogen in both groups.
CONCLUSION: The present data indicate a negative, BMI-independent association between NO levels and insulin resistance in PCOS patients. Further studies are required to clarify the role of androgens on the pathogenesis of endothelial dysfunction in PCOS and investigate androgen action and/or the gene receptor modulating NO secretion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17049715     DOI: 10.1016/j.ejogrb.2006.09.009

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  9 in total

1.  Association of Prooxidant-Antioxidant Balance with Clinical and Laboratory Parameters and Its Relation to Different Drug Regimens in Polycystic Ovary Syndrome Women with Normal BMI.

Authors:  Niloofar Heshmati; Shoaleh Shahgheibi; Bahram Nikkhoo; Sabrieh Amini; Mohammad Abdi
Journal:  Indian J Clin Biochem       Date:  2016-08-31

2.  Prolonged treatment with N-acetylcysteine and L-arginine restores gonadal function in patients with polycystic ovary syndrome.

Authors:  A Masha; C Manieri; S Dinatale; G A Bruno; E Ghigo; V Martina
Journal:  J Endocrinol Invest       Date:  2009-04-15       Impact factor: 4.256

3.  Androgenicity and venous endothelial function in post-menopausal women.

Authors:  M A Maturana; M C Rubira; F Consolim-Colombo; M C Irigoyen; P M Spritzer
Journal:  J Endocrinol Invest       Date:  2009-10-09       Impact factor: 4.256

Review 4.  The effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome.

Authors:  E Kassi; E Diamanti-Kandarakis
Journal:  J Endocrinol Invest       Date:  2008-12       Impact factor: 4.256

Review 5.  Oxidative Stress and Polycystic Ovary Syndrome: A Brief Review.

Authors:  Masoumeh Mohammadi
Journal:  Int J Prev Med       Date:  2019-05-17

Review 6.  Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients.

Authors:  Tabatha Petrillo; Elisa Semprini; Veronica Tomatis; Melania Arnesano; Fedora Ambrosetti; Christian Battipaglia; Alessandra Sponzilli; Francesco Ricciardiello; Andrea R Genazzani; Alessandro D Genazzani
Journal:  Biomedicines       Date:  2022-08-09

7.  Impact of exercise and metabolic disorders on heat shock proteins and vascular inflammation.

Authors:  Earl G Noble; Garry X Shen
Journal:  Autoimmune Dis       Date:  2012-12-17

8.  Nitric oxide-induced polycystic ovaries in the wistar rat.

Authors:  Fatemeh Hassani; Manizheh Karami; Ph D 1 1; Mohammad Reza Jalali Nadoushan; Poopak Eftekhari Yazdi
Journal:  Int J Fertil Steril       Date:  2012-06-19

9.  Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome.

Authors:  Abu Saleh Md Moin; Thozhukat Sathyapalan; Ilhame Diboun; Mohamed A Elrayess; Alexandra E Butler; Stephen L Atkin
Journal:  Sci Rep       Date:  2021-03-05       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.